The Trial Lawyer Magazine Logo

Pradaxa (Dabigatran) Trials Continue Nationwide
Pradaxa (Dabigatran) Trials Continue Nationwide

In 2018, a federal jury found that Boehringer Ingelheim Pharmaceuticals Inc. was not forthright about the risk of potential bleeding injuries with its drug, Pradaxa (Dabigatran), and the jury awarded the plaintiff $250,000 for medical expenses and pain and suffering, as well as $1 million in punitive damages. This was the first trial win for plaintiffs, after the manufacturer had succeeded at three prior trials.

Read the source article at Legal News & Business Law News

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram